(GDRX) Goodrx Holdings - Overview
Sector: Healthcare | Industry: Health Information Services | Exchange: NASDAQ (USA) | Market Cap: 969m USD | Total Return: -23.6% in 12m
Avg Turnover: 5.03M
EPS Trend: 91.2%
Qual. Beats: 0
Rev. Trend: 87.5%
Qual. Beats: 2
Warnings
Altman Z'' -1.65 < 1.0 - financial distress zone
Tailwinds
No distinct edge detected
GoodRx Holdings, Inc. (GDRX) operates a digital healthcare platform focused on drug price transparency and consumer savings in the United States. The company aggregates data to provide geographically relevant prescription pricing and facilitates access to negotiated rates through its price comparison engine.
The business model relies on partnerships with pharmacy benefit managers (PBMs) to route consumer transactions, generating revenue primarily through administrative fees when a discount code is used at the point of sale. Beyond its core prescription marketplace, the company diversified into subscription programs, pharmaceutical manufacturer marketing solutions, and telehealth services via GoodRx Care. The Health Care Technology sector often utilizes such marketplace models to capture value from the high fragmentation and price opacity inherent in the U.S. pharmaceutical supply chain.
In addition to human healthcare, GoodRx provides pricing solutions for the veterinary market, covering medications for dogs, cats, and other pets. For a deeper analysis of these revenue streams and valuation metrics, consider reviewing the comprehensive data available on ValueRay. Headquartered in Santa Monica, California, the firm has operated since 2011 as a centralized intermediary between consumers, PBMs, and retail pharmacies.
- Prescription transaction volume depends on pharmacy benefit manager network stability
- Pharma manufacturer solutions revenue growth expands high-margin advertising segments
- Retail pharmacy consolidation reduces consumer access points for discount coupons
- Direct-to-consumer marketing spend efficiency determines quarterly adjusted EBITDA margins
- Legislative changes to drug pricing transparency impact third-party discount competitiveness
| Net Income: 20.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -0.79 > 1.0 |
| NWC/Revenue: 51.69% < 20% (prev 54.78%; Δ -3.09% < -1%) |
| CFO/TA 0.08 > 3% & CFO 170.3m > Net Income 20.6m |
| Net Debt (310.6m) to EBITDA (175.2m): 1.77 < 3 |
| Current Ratio: 1.47 > 1.5 & < 3 |
| Outstanding Shares: last quarter (341.4m) vs 12m ago -10.07% < -2% |
| Gross Margin: 86.56% > 18% (prev 0.94%; Δ 8.56k% > 0.5%) |
| Asset Turnover: 47.51% > 50% (prev 61.56%; Δ -14.05% > 0%) |
| Interest Coverage Ratio: 2.26 > 6 (EBITDA TTM 175.2m / Interest Expense TTM 39.4m) |
| A: 0.20 (Total Current Assets 1.27b - Total Current Liabilities 859.2m) / Total Assets 2.02b |
| B: -0.70 (Retained Earnings -1.41b / Total Assets 2.02b) |
| C: 0.05 (EBIT TTM 89.1m / Avg Total Assets 1.66b) |
| D: -1.01 (Book Value of Equity -1.41b / Total Liabilities 1.40b) |
| Altman-Z'' = -1.65 = D |
| DSRI: 1.37 (Receivables 232.7m/172.0m, Revenue 787.9m/797.4m) |
| GMI: 1.08 (GM 86.56% / 93.84%) |
| AQI: 0.64 (AQ_t 0.35 / AQ_t-1 0.56) |
| SGI: 0.99 (Revenue 787.9m / 797.4m) |
| TATA: -0.07 (NI 20.6m - CFO 170.3m) / TA 2.02b) |
| Beneish M = -2.95 (Cap -4..+1) = A |
As of June 01, 2026, the stock is trading at USD 2.92 with a total of 1,988,686 shares traded.
Over the past week, the price has changed by +14.06%,
over one month by +23.73%,
over three months by +34.56% and
over the past year by -23.56%.
Goodrx Holdings has received a consensus analysts rating of 3.88. Therefore, it is recommended to buy GDRX.
- StrongBuy: 7
- Buy: 1
- Hold: 7
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 3.2 | 8.9% |
P/E Trailing = 47.6667
P/E Forward = 5.4407
P/S = 1.1391
P/B = 1.4429
Revenue TTM = 787.9m USD
EBIT TTM = 89.1m USD
EBITDA TTM = 175.2m USD
Long Term Debt = 482.4m USD (from longTermDebt, last quarter)
Short Term Debt = 9.98m USD (from shortTermDebt, last quarter)
Debt = 546.3m USD (corrected: LT Debt 482.4m + ST Debt 9.98m) + Leases 53.9m
Net Debt = 310.6m USD (calculated: Debt 546.3m - CCE 235.7m)
Enterprise Value = 1.28b USD (968.6m + Debt 546.3m - CCE 235.7m)
Interest Coverage Ratio = 2.26 (Ebit TTM 89.1m / Interest Expense TTM 39.4m)
EV/FCF = 9.72x (Enterprise Value 1.28b / FCF TTM 131.6m)
FCF Yield = 10.29% (FCF TTM 131.6m / Enterprise Value 1.28b)
FCF Margin = 16.71% (FCF TTM 131.6m / Revenue TTM 787.9m)
Net Margin = 2.61% (Net Income TTM 20.6m / Revenue TTM 787.9m)
Gross Margin = 86.56% ((Revenue TTM 787.9m - Cost of Revenue TTM 105.9m) / Revenue TTM)
Gross Margin QoQ = 78.38% (prev 91.03%)
Tobins Q-Ratio = 0.63 (Enterprise Value 1.28b / Total Assets 2.02b)
Interest Expense / Debt = 7.22% (Interest Expense 39.4m / Debt 546.3m)
Taxrate = 46.16% (26.1m / 56.5m)
NOPAT = 48.0m (EBIT 89.1m * (1 - 46.16%))
Current Ratio = 1.47 (Total Current Assets 1.27b / Total Current Liabilities 859.2m)
Debt / Equity = 0.88 (Debt 546.3m / totalStockholderEquity, last quarter 622.0m)
Debt / EBITDA = 1.77 (Net Debt 310.6m / EBITDA 175.2m)
Debt / FCF = 2.36 (Net Debt 310.6m / FCF TTM 131.6m)
Total Stockholder Equity = 620.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.24% (Net Income 20.6m / Total Assets 2.02b)
RoE = 1.01% (Net Income TTM 20.6m / Total Stockholder Equity 2.03b)
RoCE = 3.55% (EBIT 89.1m / Capital Employed (Equity 2.03b + L.T.Debt 482.4m))
RoIC = 4.51% (NOPAT 48.0m / Invested Capital 1.06b)
WACC = 7.06% (E(968.6m)/V(1.51b) * Re(8.85%) + D(546.3m)/V(1.51b) * Rd(7.22%) * (1-Tc(0.46)))
Discount Rate = 8.85% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -91.11 | Cagr: -6.81%
[DCF] Terminal Value 77.97% ; FCFF base≈116.8m ; Y1≈133.9m ; Y5≈197.1m
[DCF] Fair Price = 25.36 (EV 2.97b - Net Debt 310.6m = Equity 2.65b / Shares 104.7m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 91.25 | EPS CAGR: 10.36% | SUE: 0.0 | # QB: 0
Revenue Correlation: 87.55 | Revenue CAGR: 2.95% | SUE: 4.0 | # QB: 2
EPS current Quarter (2026-06-30): EPS=0.08 | Chg30d=+1.38% | Revisions=-17% | Analysts=11
EPS next Quarter (2026-09-30): EPS=0.08 | Chg30d=-3.57% | Revisions=-38% | Analysts=11
EPS current Year (2026-12-31): EPS=0.31 | Chg30d=-1.92% | Revisions=-29% | GrowthEPS=-11.2% | GrowthRev=-2.6%
EPS next Year (2027-12-31): EPS=0.36 | Chg30d=-2.34% | Revisions=-23% | GrowthEPS=+15.5% | GrowthRev=+5.5%
[Analyst] Revisions Ratio: -38%